peptabody-EGF

an apoptosis inducer targeting ErbB1 receptor overexpressing cancer cells; the protein complex contains 5 human EGF ligand domains, which confer specific binding towards the extracellular portion of EGFR

Networked: 1 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Cloutier, Sylvain M: 1 article (11/2006)
2.	Deperthes, David: 1 article (11/2006)
3.	Fattah, Omar M: 1 article (11/2006)
4.	Felber, Loyse M: 1 article (11/2006)
5.	Gauthier, Eric R: 1 article (11/2006)
6.	Gygi, Christian M: 1 article (11/2006)
7.	Jichlinski, Patrice: 1 article (11/2006)
8.	Kündig, Christoph: 1 article (11/2006)
9.	Leisinger, Hans-Jürg: 1 article (11/2006)
10.	Mach, Jean Pierre: 1 article (11/2006)

Related Diseases

1.

Neoplasms (Cancer) 11/15/2006 - "Furthermore, the antitumor action provoked by the peptabody-EGF was greatly superior than antibody mediated effects when tested on EGFR overexpressing cancer cell lines. " 11/15/2006 - "Peptabody-EGF treated cancer cells exhibited typical characteristics of apoptosis, which was found to be induced within 30 min after the addition of the peptabody-EGF. " 11/15/2006 - "Receptor binding of the peptabody-EGF had a strong antiproliferative effect on different cancer cell lines overexpressing EGFR. " 11/15/2006 - "Peptabody-EGF: a novel apoptosis inducer targeting ErbB1 receptor overexpressing cancer cells."